Pharmacyclics PT Raised to $103.00 at Roth Capital (PCYC
Posted by Kristian Gore on Apr 22nd, 2013 Roth Capital raised their price target on shares of Pharmacyclics (NASDAQ: PCYC) from $93.00 to $103.00 in a research note issued on Monday, Analyst Ratings Network reports. The firm currently has a “buy” rating on the stock.
Other equities research analysts have also recently issued reports about the stock. Analysts at TheStreet downgraded shares of Pharmacyclics from a “buy” rating to a “hold” rating in a research note to investors on Thursday, April 4th. Separately, analysts at Wedbush set a $165.00 price target on shares of Pharmacyclics in a research note to investors on Wednesday, March 20th. They now have an “outperform” rating on the stock. Finally, analysts at Morgan Stanley initiated coverage on shares of Pharmacyclics in a research note to investors on Tuesday, March 19th. They set an “equal weight” rating on the stock.
Seven equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. Pharmacyclics presently has a consensus rating of “Buy” and an average price target of $94.09.
We should probably feel safe in disregarding a downgrade coming from "The Street", which is merely an automated system which will point out that the p/e ratio is high and revenues low. I don't know why they just don't shut their laughably irrelevant rating system down.